The heterogeneity of EC, including variations in IGF1 expression across tumour subtypes, further complicates the development of effective therapies and underscores the need for predictive biomarkers to identify patients most likely to benefit from IGF1-targeted treatments [34,35]. This evidence concerns the gene IGF1 and neoplasm.